Positron emission tomography in uro-oncology

Cancer Imaging

Volumn 5, Issue 1, 2005, Pages 1-7

  Hain, S F ^a,b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

FDG PET; Prostate; Testicular cancer.; Uro oncology

Indexed keywords

ARTICLE; BLADDER TUMOR; FEMALE; HUMAN; KIDNEY TUMOR; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; SCINTISCANNING; TESTIS TUMOR; URINARY TRACT CANCER;

FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 33645258001     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2005.0001     Document Type: Article

References (52)

1. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67: 790-7.
2. Mikhaeel NG, Timothy AR, Hain S, O'Doherty MJ, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 39: 543-53.
3. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18 fluorine-labelled deoxyglucose. J Urol 1996; 155: 994-8.
4. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomograpy studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 108-11.
5. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86: 512-6.
6. Oyama N, Akino H, Suzuki Y et al. The increased accumulation of
7. fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29: 623-9.
8. Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18F FDGPET for the assessment of residual masses on CT after treatment of lymphomas. Ann Oncol 2000; 11: S147-S50.
9. Hain SF, O'Doherty MJ, Timothy AR et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83: 863-9.
10. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 31-5.
11. Sanz G, Robles JE, Gimenez M, Arocena J, Sanchez D, Rodriguez-Rubio F. Positron emission tomography with 18 fluorine-labelled deoxyglucose: utility in localized and advance prostate cancer. BJU Int 1999; 84: 1028-31.
12. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-[F- 18]fluoro-D-glucose. Radiology 1996; 199: 751-6.
13. Morris MJ, Akhurst T, Osman I et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002; 59: 913-8.
14. Yeh SD, Imbriaco M, Larson SM, Garza D, Zang JJ, Kalaigian H et al. Detection of bony metastases of androgenindependent prostate cancer by FDG-PET. Nucl Med Biol 1996; 23: 693-7.
15. Jadvar H, Pinski JK, Conti PS. FDG PET in suspected recurrent and metastatic prostate cancer. Oncol Rep 2003; 10: 1485-8.
16. Chang CH, Wu HC, Tsai JJ et al. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 2003; 70: 311-5.
17. Oyama N, Akino H, Suzuki Y et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001; 22: 963-9.
18. Kotzerke J, Prang J, Neumaier B et al. Experience with carbon- 11 choline positron emission tomography in prostate cancer. Eur J Nucl Med 2000; 27: 1415-9.
19. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using choline-11-choline. J Nucl Med 1998; 39: 990-5.
20. Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43: 181-6.
21. Oyama N, Miller TR, Dehdashti F et al. 11C-acetate PET imaging of prostate cancer; detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44: 549-55.
22. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography of residual radiological abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996; 14: 1637-41.
23. Cremerius U, Effert PJ, Adam G et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998; 39: 815-22.
24. Tsatalpas P, Beuthien-Baumann B, Kropp J et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 2002; 68: 157-63.
25. Sugawara Y, Zasadny KR, Grossman HB et al. Germ cell tumour: differentiation of viable tumor, mature teratoma and necrotic tissue with FDG PET and kinetic modelling. Radiology 1999; 211: 249-56.
26. Duchesne GM, Stenning SP, Aass N et al. Radiotherapy after chemotherapy for metastatic seminoma-a diminishing role. MRC testicular Working Party. Eur J Cancer 1997; 33: 829-35.
27. De Santis M, Bokemeyer C, Becherer A et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001; 19: 3740-4.
28. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-2- deoxy-D-glucose positron emission tomography is a reliable predictor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034-9.
29. Mikhaeel NG, Timothy AR, O'Doherty MJ et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non- Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000; 39: 543-53.
30. Schelling M, Avril N, Nahrig J et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95.
31. Smith IC, Welch AE, Hutcheon AW et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676-88.
32. Bokemeyer C, Kollmannsberger C, Oechsle K et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 2002; 86: 506-11.
33. Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for Stage I testicular teratoma. J Clin Oncol 1992; 10: 1762-8.
34. Horwich A. Testicular cancer. In: Oncology-a multidisciplinary textbook, Horwich A, ed. London: Chapman and Hall, 1995: 485-98.
35. Huddart R, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 1513: 23.
36. Hain SF, O'Doherty MJ, Timothy AR et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27: 590-4.
37. Cremerius U, Wildberger JE, Borchers H et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results in 50 patients. Urology 1999; 54: 900-4.
38. Albers P, Bender H, Yilmaz H et al. Positron emission tomography in the clinical staging of patients with stages I and II testicular germ cell tumours. Urology 1999; 53: 808-11.
39. Lassen U, Daugaard G, Eigtved A et al. Whole body FDG-PET in patients with stages I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003; 30: 396-402.
40. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe 1999; 38: 46-50.
41. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997; 24: 615-20.
42. Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996; 37: 180-5.
43. Bachor R, Kotzerke J, Gottfried HW et al. Positron emission tomography in the diagnosis of renal cell carcinoma. Urologe 1996; 35: 146-50.
44. Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52: 510-5.
45. Ramdave S, Thomas GW, Berlangieri SU et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166: 825-30.
46. Miyakita H, Tokunaga M, Onda H et al. Significance of 18Ffluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9: 15-8.
47. Kand DE, White Jr RL, Zuger JH et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2003; 171: 1806-9.
48. Hain SF, Gleadle J, Maisey MN. FDG-PET in the differentiation of thrombus and tumour in renal cell carcinoma. Clin Nucl Med 1999; 24: 819-20.
49. Aide N, Cappele O, Bottet P et al. Efficiency of [(18F)]FDG PET in characterising renal cancer detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003; 30: 1236-45.
50. Majhail NS, Urbain JL, Albani JM et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21: 3995-4000.
51. Seto E, Segall GM, Terris MK. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology 2000; 55: 286.
52. Safaei A, Figlin R, Hoh CK et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 2002; 57: 56-62.